NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/12/2024
Voltar para busca
Dado oficial do USPTO
HIKMA 503B
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
HIKMA 503B
ST13
US500000090795613Classe
5, 16, 44
Pedido
90795613
Registro
7634125
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
31/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 16, 44
Data de depósito
25/06/2021
Data de registro
31/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/12/2024
Última transação
31/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2021-06-00
Primeiro uso no comércio
2021-12-00
Código do desenho
4
Tipo de titular
03
Localização do titular
Berkeley Heights, NJ, US
Examinador
FAIRBANKS, RONALD L
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Hikma Injectables USA Inc.
Representantes
Michelle E. Tochtrop PEARNE & GORDON LLP
Classificação técnica
Classes Nice
Classe 5Classe 16Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medicinal preparations and substancessystemic anti-infectivespharmaceutical and medicinal substances for the preventioncuringtreatment of viralmetabolicalimentaryendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalparasiticpsychiatricimmune system related diseases and disorders; pharmaceutical and medicinal substances for the preventioncuringtreatment of allergiesinflammationpaininfectious diseasesblood diseases and disordersnervous system diseases and disordersmalignant neoplastic diseases and disordersimmunomodulating agent diseases and disorders; chemical preparations for pharmaceutical or medical purposesfor viralmetabolicalimentaryendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalparasiticpsychiatricimmune system related diseases and disordersallergiesinflammationpaininfectious diseasesblood diseases and disordersnervous system diseases and disordersmalignant neoplastic diseases and disordersimmunomodulating agent diseases and disorders
Classe 16
Papercardboard; articles of paper or cardboardbagsenvelopespaper packaging materialspacking paperpacking cardboardnotebooksnotepadsfoldersbookmarkerscalendarsboxescoastersstationery paperpostersposter boardpaper stationery; printed matterprinted booksbookletsjournalsmagazinesnewspapersperiodicalspamphletsbrochuresmanualsleafletsinformational flyersinformational sheetsnewslettersinstructional worksheets all in the fields of medicinemedical technologypharmaceuticalshealthcare; printed instructional and teaching materialsprinted booksbookletsjournalsmagazinesnewspapersperiodicalspamphletsbrochuresmanualsleafletsinformational flyersinformational postersinformational sheetsnewslettersinstructional worksheets all in the fields of medicinemedical technologypharmaceuticalshealthcare; stationery; adhesive materialsadhesives for stationery or household purposesadhesive stickersadhesive notepads
Classe 44
Pharmaceutical compounding services; medical testing and analysis for diagnostic or treatment purposes; genetic testing for medical purposes; advisory services relating to healthcare being medical diagnostic and treatment advisory services relating to health
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/12/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
27/10/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/10/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
27/10/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/10/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
27/10/2024
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
27/10/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
03/07/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
03/07/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/04/2024
GNRT
NON-FINAL ACTION E-MAILED
08/04/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/04/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/01/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/01/2024
IUAF
USE AMENDMENT FILED
20/12/2023
EISU
TEAS STATEMENT OF USE RECEIVED
20/12/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28/06/2023
EX1G
SOU EXTENSION 1 GRANTED
26/06/2023
EXT1
SOU EXTENSION 1 FILED
26/06/2023
EEXT
SOU TEAS EXTENSION RECEIVED
26/06/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
27/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/11/2022
PUBO
PUBLISHED FOR OPPOSITION
01/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/10/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/09/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/09/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/09/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/03/2022
GNRT
NON-FINAL ACTION E-MAILED
24/03/2022
CNRT
NON-FINAL ACTION WRITTEN
24/03/2022
DOCK
ASSIGNED TO EXAMINER
16/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2021
NWAP
NEW APPLICATION ENTERED
29/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HIKMA 503B ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.